ReachRxResearch
Home
Research
Sign Up
The addition of mirabegron in pediatric lower urinary tract dysfunction: A large single-center experience
Back to Research Hub
  1. Home
  2. Research Hub
  3. The addition of mirabegron in pediatric…

The addition of mirabegron in pediatric lower urinary tract dysfunction: A large single-center experience

Journal of Pediatric Urology·August 31Open Access
PediatricsConfirms priorLower Urinary Tract DysfunctionNeurogenic BladderRetrospective Cohort StudyBeta-3 Adrenergic AgonistPediatricMyrbetriqMirabegron

Summary

View source

What was studied

Efficacy and safety of mirabegron (beta-3 adrenergic agonist) in 192 pediatric patients with neurogenic bladder or non-neurogenic lower urinary tract dysfunction (LUTD), used as monotherapy or concurrent therapy, at a single center from 2018–2024 with median follow-up of 12 months.

Key findings

65% of patients (n=124) achieved partial improvement or greater, with a median time-to-improvement of 7 months. Side effects occurred in 13% (n=25), including headache (4%), nausea (4%), and hypertension (2%). No patient factors—age, sex, indication, behavioral comorbidities, or concurrent medications—predicted symptom improvement.

Study limitations

Single-center, retrospective observational design limits generalizability. Symptom assessment relied on clinical documentation rather than validated questionnaires or urodynamic outcomes. No control group for comparison.

Clinical implications

Mirabegron appears safe and effective for pediatric LUTD, with a 65% improvement rate and a modest 13% side-effect rate. Consider it as monotherapy or add-on to anticholinergics in children with neurogenic or non-neurogenic bladder dysfunction, and counsel families that improvement may take up to 7 months.

Caveats

  • Brand name 'Myrbetriq' inferred from generic 'mirabegron'; the paper does not specify a brand name.
  • Symptom improvement was defined by clinical documentation, not validated instruments (e.g., DVSS), which may introduce assessment variability.
  • The paper is dated 2026; results reflect a single institutional experience and may not generalize to other pediatric settings.

Related Questions

Explore related topics

What is the evidence for mirabegron versus oxybutynin in pediatric overactive bladder?How does mirabegron perform as add-on therapy to anticholinergics in children with neurogenic bladder?What are the cardiovascular safety considerations of mirabegron in the pediatric population?

Publication Details

Year
2026
Journal
Journal of Pediatric Urology
Sample Size
n=192
Source
View article
Keep scrolling
More content below.
Up Next